Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Geode Capital Management LLC reduced its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 846,249 shares of the biopharmaceutical company’s stock after selling 39,575 shares during the period. Geode Capital Management LLC owned approximately 0.94% of Chimerix worth $787,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Chimerix in the second quarter valued at approximately $137,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Trading Down 6.9 %

NASDAQ CMRX opened at $3.25 on Friday. The stock has a market capitalization of $292.29 million, a price-to-earnings ratio of -3.46 and a beta of 0.36. The business’s 50 day moving average is $1.97 and its two-hundred day moving average is $1.27. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $3.80.

Wall Street Analyst Weigh In

CMRX has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Chimerix in a report on Monday, December 30th. Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.